Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 3 · 37.5%Low 4 · 50%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Donepezil vs placebo · Adverse events (Side Effects Checklist)
  Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Very low
Related · question page
- Atypical antipsychotics vs placebo · Adverse effects (AEs)
  Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
  RR 4.19
  11 studies · 974 participants
  Low
Direct match · question page
- Neurohormones vs placebo · Adverse effects
  Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
  RR 0.58 [0.38, 0.89]
  10 studies · 863 participants
  Very low
Direct match · question page
- Galantamine plus risperidone vs placebo plus risperidone · Adverse events (Side Effects Checklist)
  Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
  OR 5.57 [1.42, 21.86]
  1 study · 40 participants
  Low
Related · question page
- Antidepressants vs placebo · Adverse effects
  Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
  RR 4.16
  10 studies · 815 participants
  Low

Intervention not reported

Adverse effects Measured by: worsening of adaptive behavior or autism symptom severity · patients with young children (less than six years old) with autism spectrum disorders (ASD)

The review found no eligible studies for this question.

1 finding from 1 review

Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD) 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Attention deficit hyperactivity disorder (ADHD)‐related drugs vs placebo

Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

It is very uncertain whether attention deficit hyperactivity disorder (ADHD)‐related drugs changes adverse effects compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
RR 3.42
9 studies · 511 participants
Very low

Galantamine plus risperidone vs placebo plus risperidone

Side effects or other adverse events · children and adolescents with a diagnosis of autism

Galantamine plus risperidone may leads to higher adverse events (Side Effects Checklist) compared with placebo plus risperidone (low certainty).

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
OR 5.57 [1.42, 21.86]
1 study · 40 participants
Low

Antidepressants vs placebo

Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

Antidepressants may leads to higher adverse effects compared with placebo (low certainty).

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
RR 4.16
10 studies · 815 participants
Low

Neurohormones vs placebo

Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

It is very uncertain whether neurohormones changes adverse effects compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
RR 0.58 [0.38, 0.89]
10 studies · 863 participants
Very low

Atypical antipsychotics vs placebo

Adverse effects (AEs) · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

Atypical antipsychotics may leads to higher adverse effects (AEs) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
RR 4.19
11 studies · 974 participants
Low

Donepezil vs placebo

Side effects or other adverse events · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Memantine vs placebo

Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD

Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
OR 0.64 [0.17, 2.39]
2 studies · 144 participants
Low